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ABSTRACT
Introduction: Given the potentially fatal consequences of inadequate adherence with oral anticancer
treatment in persons with cancer, understanding the determinants of adherence is vital. This paper
aims at identifying psychosocial determinants of adherence to oral anticancer treatment.
Methods: We reviewed the literature on psychosocial determinants of adherence with oral anticancer
treatment, based on published literature in English, from 2015 to present. Literature searches were
performed in PubMed, Embase, Web of Science, Cochrane library, Emcare, and PsychINFO, with
‘cancer’, ‘medication adherence’, ‘psychology’, and ‘oral anticancer treatment’ as search terms. The
obtained 608 papers were screened by two independent reviewers.
Results: In the 25 studies identified, illness perceptions, medication beliefs, health beliefs, and depression
were found to be the major psychosocial determinants of adherence to oral anticancer treatment; sociode-
mographic and clinical characteristics were found to be of no major importance. The quality of the identi-
fied studies as assessed by two independent reviewers was found to be acceptable overall. The majority of
papers were from North America and focused on patients with breast cancer; sample size varied from 13
to 1371; adherence was assessed with questionnaires derived from various theoretical models, pill counts
and electronic pharmacy records; illness perceptions reflecting adaptive coping, and medication beliefs
reflecting high necessity and low concerns were found to be associated with adherence.
Conclusion: Psychosocial concepts are major determinants of adherence with oral anticancer treat-
ment. ‘Beliefs about medicines’ and ‘illness perceptions’ in particular determine adherence with this
treatment. Studies aiming at impacting adherence would benefit from interventions with a solid basis
in behavioral theory in order to help health care providers explore and address illness perceptions and
medication beliefs. Pre-consultation screening of adherence behavior may be a helpful supportive
approach to improve adherence. Blaming the victim (‘patients should be educated about the import-
ance of adherence’) is better replaced by encouraging health professionals to identify and address
maladaptive psychosocial determinants of adherence.
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Introduction
There is discernable optimism in the introductions to many
scientific papers on oral anticancer treatment. Authors state
that taking the medication at home represents an important
improvement over chemotherapy delivered in a hospital set-
ting [1,2]. A disadvantage mentioned by these authors is the
absence of control by health care providers over the medica-
tion-taking by patients in their homes [3,4]. All authors
emphasize how ‘compliance’ with oral anticancer treatment
is crucial, impacting directly on mortality [5]. The surprise or
the disappointment in health care providers over a lack of
patient adherence is often tangible. For behavioral scientists
who study the subject of ‘compliance’, it is not really a sur-
prise to read in virtually all papers in the area of oral anti-
cancer treatment how sociodemographic and clinical
characteristics turn out to be not related to ‘compliance’
while psychosocial factors are; the surprise seems to reflect
the lack of or modest inclusion of psychosocial concepts in
the papers’ study designs. Despite this, in the Discussion sec-
tions of those papers, the mantra of ‘… patients, therefore,
should be educated about the importance of being compli-
ant with oral anticancer treatment’ often follows [6,7].
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The lyric ‘We don’t need no education …’ from the Pink
Floyd song ‘Another brick in the wall’ articulates the direc-
tion research and clinical care, we believe, should go when it
comes to oral anticancer treatment. As stated in the WHO
report on Adherence to long-term therapies, ‘patients need
to be supported, not blamed’ in their attempts to adhere to
medication ‘regimes’ [8]. ‘Compliance’ refers to ‘… the
extent to which a patient’s behavior in terms of taking medi-
cation, following diets, or implementing lifestyle changes
coincides with medical or health advice’ [9], whereas
‘adherence’ is defined as ‘the extent to which a person’s
behavior – taking medication, following a diet, and/or exe-
cuting lifestyle changes, corresponds with agreed recommen-
dations from a healthcare provider’ [8] . Some researchers go
one step further and prefer the word ‘concordance’, defined
as ‘… a process of the consultation in which prescribing is
based on partnership’. Steiner and Earnest elegantly outline
some problematic issues in the concept of ‘compliance’: ‘…
noncompliance exaggerates the physician’s control over the
process of taking medications … ‘compliance’ implies that
the patient must take the medication as prescribed to obtain
benefit … ‘noncompliance ‘as a term creates a clinically
unjustifiable distinction between persons who take all of
their pills as prescribed and those who deviate from the pre-
scription in any way … and does not accurately represent
patients’ motivations for choosing to take their medications
a certain way’ (p. 926) [10].
Discussing the concepts of compliance, adherence, and
concordance aims to outline the context of research on the
degree to which patients with various types of cancer take
their oral anticancer treatment as intended – as intended by
prescribing health care professionals. A number of recent lit-
erature reviews have summarized the subject [11–16]. A
qualitative study on oral chemotherapy adherence identified
10 papers; ‘driving’ and ‘disabling’ factors were found to be
the two major determinants of adherence [11]. A meta-ana-
lysis encompassing seven studies on interventions to pro-
mote adherence to endocrine therapy in patients with breast
cancer found ‘bi-directional communication’ between patient
and health care provider to impact positively on adherence
[12]. Greer and colleagues performed a systematic review of
adherence with oral antineoplastic therapies and identified
the problems patients report in adhering to the prescribed
medication – based on empirical studies to 2015, however
[13]. The systematic review by Murphy and colleagues
included a fairly large number of studies (29), however, the
study did not focus explicitly on psychosocial determinants
to adherence [14]. The recent scoping review by Rosenberg
et al. focused on interventions to enhance adherence to oral
antineoplastic agents – without an explicit focus on psycho-
social determinants, however [15]. Important as these papers
are, they do not explicitly focus on examining psychosocial
determinants of adherence with oral anticancer treatment.
The two most recent review papers on adherence with oral
anticancer drugs concentrate on ‘factors influencing non-
adherence to oral anti-neoplastic drugs’ [16], and on
‘interventions to enhance adherence to oral anti-neoplastic
agents’ [17] – without a focus on psychosocial determinants
of adherence. Our paper aims to contribute to this literature,
by (a) updating the literature review [2015–2020], and (b) by
focusing explicitly on psychosocial determinants of oral anti-
cancer treatment in persons with cancer. Given the state-of-
the-art concerning ‘adherence’ research and clinical interven-
tion, we focus on perceptions by patients of their illness and
the associated medication, and the relation of these percep-
tions with adherence behavior.
Theoretical models help in conceptualizing determinants
of adherence behavior. The WHO report on ‘Adherence to
long-term therapies’ distinguishes five domains that poten-
tially impact on adherence: social/economic, therapy-related,
patient-related, condition-related, and health system/health
care team factors, suggesting domains for interventions [8].
In the Common Sense Model, cognitive and emotional repre-
sentations (illness perceptions) of a health threat elicit cop-
ing procedures that, after being appraised for their
effectiveness in adapting to the health threat, are adjusted
to or are perceived as being adequate in reducing or remov-
ing the threat. Schematically, the Common Sense Model can
be summarized as: illness perceptions determine coping
behavior which in its turn determines outcome. A model
from the behavioral sciences with an explicit focus on target-
able determinants of adherence behavior is the so-called
Extended Common Sense Model [18].
In the Extended Common Sense Model, in addition to ill-
ness perceptions, medication beliefs are added to predict
adherence to medication such as oral anticancer medication.
The WHO model on adherence is extremely valuable in its
emphasis on encompassing a wider set of determinants than
only the individual patient. The Common Sense Model and
its specification for adherence, the Extended Common Sense
Model, offer specific psychosocial concepts (i.e. operational-
ized in validated questionnaires that assess illness percep-
tions and medication beliefs) that allow studying
psychosocial determinants of adherence in one of the
domains of the WHO model, i.e. the patient. The Extended
Common Sense model guided our review of the literature on
adherence with oral anticancer treatment. We aimed at
examining characteristics in the domains of illness percep-
tions and medication beliefs (‘specific and general represen-
tations of treatment’) in relation to adherence with oral
anticancer treatment in persons with cancer. Given the exist-
ing literature on this topic, our review selected papers from
2015 to present. The review focuses on recent empirical
papers on adherence with oral anticancer drugs, prescribed
to adult patients; the review also focuses on identifying con-
cepts from theoretical models on adherence. The review
aims at identifying determinants of adherence in patients on
oral anticancer medication in order to allow intervening in
these determinants with a view to achieve optimal adher-
ence with this category of medication.
Methods
In cooperation with a trained librarian (JWS), a detailed, two-
stranded search strategy was composed. The following data-
bases were searched: PubMed, Embase, Web of Science,
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COCHRANE Library, Emcare, and PsycINFO. The two search
strategies used a combination of the following concepts:
cancer, medication adherence, psychology, oral anticancer
treatment. For the different concepts, all relevant keyword
variations were used, not only keyword variations in the con-
trolled vocabularies of the various databases, but the free
text word variations of these concepts as well. The search
strategy was optimized for all consulted databases, taking
into account the differences of the various controlled vocab-
ularies as well as the differences of database-specific tech-
nical variations (e.g. the use of quotation marks). The final
search was performed on February 2nd, 2020. Case reports
and meeting abstract references were excluded. The results
were limited to articles written in English. The date limit was
set to articles published from the year 2015. The biblio-
graphic databases yielded 608 references. Full details of the
search strategy can be found in Supplementary Appendix.
The CONSORT/PRISMA diagram is depicted in Figure 1.
Two reviewers reviewed the 608 abstracts of the selected
papers (PBvdM, BA in psychology, and MA in Medicine; AAK,
PhD in psychology), uncertainties were resolved through dis-
cussion. Twenty five papers fitted the selection criteria.
The quality of the 25 selected studies was assessed fol-
lowing an adaptation of the method used in a study on
adherence with another category of medication [19]; the two
reviewers who reviewed the abstracts allotted one point
each for (1) sample size over 100, (2) use of validated assess-
ment of adherence, (3) use of validated determinants of
adherence. ‘Low’ quality equaled 0 points, ‘medium’ quality 1
or 2 points, ‘high’ quality 3 points.
Results
Twenty-five studies were identified (Table 1) [4,20–43].
The studies selected were performed in the USA mainly
(12), with the UK (3), Germany (GER) (2) and Italy (ITA) (2) as
runners-up; New Zealand (NZ), Spain (ESP), Canada (CAN),
The Netherlands (NETH), Belgium (BEL), Japan (JAP) are the
countries of origin of one study each. Sample sizes varied
from 13 to 1,371 patients. Breast cancer was the diagnostic
category studied most often in this selection of studies (18),
followed by chronic myeloid leukemia CML (2) and (colo)rec-
tal cancer (2). Adherence was assessed in a number of ways:
questionnaires with solid psychometric characteristics (i.e.
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MARS [44]: Medication Adherence Report Score; MMAS [45]:
Morisky Medication Adherence Report), a medication elec-
tronic measuring system: MEMS; pill count, self-report, and
health care provider report. The psychosocial determinants
used in the selected studies are summarized in the fourth
column of Table 1: illness perceptions, health beliefs, facilita-
tors/barriers, coping, quality of life, and depression, appear
to be the most frequently used concepts, consistent with the
concepts in the Extended Common Sense Model, in particu-
lar those assessed with the Brief Illness Perception
Questionnaire (BIPQ) and the Beliefs about Medicines
Questionnaire (BMQ). The WHO model shows its validity by
the concepts listed in the Results column of Table 1: (finan-
cial) barriers to therapy, social support, psychological issues
(e.g. anxiety), depression, and self-efficacy are given in the
WHO model, and mentioned as additional determinants of
adherence in the Results section of our literature review.
Furthermore, depression and quality of life turn up as
additional concepts associated with adherence. Adherence
appears to be negatively associated with the perception by
patients of psychological and financial barriers, low illness
coherence, high levels of distress (anxiety, depression), low
perceived behavioral control, negative medication beliefs,
and fear of side effects. Adequate social support, illness per-
ceptions that adequately represent the nature of the illness
and its required medical management, high perceived neces-
sity of the medication, and self-efficacy for taking medication
appear to be associated with a higher level of adherence.
These findings overall are quite in line with the established
body of research on adherence [8–10]. A not quite surprising
but nevertheless important finding from the literature search
is how nine papers in Table 1 have been published in psych-
ology journals; in the other selected papers, one or more
psychologists usually were a part of the research team. This
not only supports the validity of the search strategy, it also
illustrates how many papers without authors with behavioral
expertise tend to apply biomedical designs, with rather pre-
dictable results as a consequence.
The quality of the 25 papers amounted to ‘low’ (score 0):
n¼ 5, ‘medium’ (score 1 or 2): n¼ 12, ‘high’ (score 3): n¼ 8.
Discussion
Reviewing the empirical literature on adherence with oral
anticancer treatment in persons with cancer is a timely
endeavor, given the rapidly increasing role of this innovative
way of delivering medication (i.e. rather than intravenous
chemotherapy). Given the state-of-the-art regarding adher-
ence, in the review we focused on psychosocial determinants
of adherence. Given earlier reviews, our review includes
papers published from 2015 to 2020. Four percent of papers
that were identified in the literature searches fitted the criter-
ion of psychosocial determinants of adherence with oral anti-
cancer treatment: 25 papers were the basis for our review.
Consistent with earlier work, adherence appears to be not
determined by sociodemographic or clinical characteristics
(except a few exceptions, e.g. [5]): more importantly appear
to be determinants that are part of the Extended Common
Sense Model, i.e. illness perceptions, medication beliefs, cop-
ing and more or less stable personality characteristics such
as anxiety and depression [24,25,29,31,32,35,38,39]. Earlier,
more or less comparable reviews published similar results
(e.g. [11,46–48]): they reflect the upshot of the WHO report
on adherence in identifying five categories of adherence: the
patient, the condition, the treatment, the health care organ-
ization, and sociocultural/economic conditions [8]. The
reviewed studies in Table 1 use a wide variety of theoretical
backgrounds; not all, therefore, would fit seamlessly into the
Extended Common Sense Model. Nevertheless virtually all
concepts used in the studies do attempt to assess the
patient’s views regarding medication and the medical condi-
tion, i.e. psychosocial determinants.
The issue of interventions in adherence of persons on oral
anticancer treatment is discussed in quite a few important
papers. Greer et al. review 12 intervention studies and con-
clude that treatment monitoring especially in a pharmacy
context may impact positively on adherence, although these
authors caution against too much optimism [13]. A number
of substantial methodological issues make for cautious inter-
pretation. Rosenberg et al.’s study is more or less a sequel to
the Greer et al. review [15]. Rosenberg et al. identify a some-
what larger number of studies and they share the critical
remarks by Greer et al., regarding methodological issues in
the selected empirical studies. Rosenberg et al. conclude
‘some pharmacy-directed programs, particularly those that
integrate monitoring or routine follow-up with a provider
did demonstrate efficiency’ [15].
Suggesting that ’patients should be educated’ about the
necessity of adhering to prescribed medication seems not to
be very productive [40,49]. One might even make the case,
consistent with the analyses in the WHO report on
Adherence, that it is not the patient but rather the health
care provider who should be educated about adherence as a
complex aspect of human behavior. ‘Adherence is deter-
mined to a considerable extent by cognitions (ideas, views)
and emotions (anxiety, fear, denial) about the medication
and the illness’, would be the main message about adher-
ence (cf. Jacobs et al., who emphasize the importance of
exploring illness perceptions and medication beliefs in efforts
to motivate patients to continue taking their oral anticancer
treatment 30]. Recently, ASCO/NCODA Standards appear to
integrate these suggestions to a certain extent, which must
be judged as encouraging [50].
We acknowledge a few limitations of our work. Although
the literature search was performed according to state-of-
the-art requirements (i.e. CONSORT, PRISM), the selection of
papers from the literature search may have been biased.
Furthermore, given the great variation in virtually all major
aspects of the included studies, it was not feasible to rate
the included studies on a set of predefined criteria.
In line with the previous reviews, our review points at
some suggestions for intervention: ‘explore illness percep-
tions and medication beliefs, discuss them and attempt to
have patients agree with more adaptive and constructive
perceptions’ seems to be the ‘take home message’. Cognitive
behavioral therapy offers theoretical and empirical expertise
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in this area. Theoretical models on adherence behavior (e.g.
the Extended Common Sense Model 18] could be used as a
guiding principle in intervention research [51]. Recently,
Weinman and colleagues published such a study: based on a
theoretically based model about behavior change, the
authors developed a brief screening tool to help patients dis-
close any hesitations they may have in using prescribed
medications without confronting them with all too explicit
and therefore possibly threatening items about non-adher-
ence [52]. The screening tool was found to correlate strongly
with the core questionnaire in the Extended Common Sense
Model (i.e. the Beliefs about Medicines Questionnaire, BMQ).
The authors suggest using the screening tool in order to
assess adherence in a valid manner, without social desirabil-
ity effects. Another promising approach in attempts to help
patients adhere with their oral targeted therapy was pub-
lished recently [53]. The authors discuss a Therapeutic
Patient Education (TPE) programme, consisting of two spe-
cific components: ‘self-care skills, referring to both an under-
standing of the disease and the appropriation of specific
care techniques crucial for self-management, and psycho-
social skills, which are related to patient empowerment,
whereby patients play a more active role in their care’ (p.
537). The TPE is based on psychological theory on behavior
change that is similar to the Common Sense Model of Self-
Regulation. The authors are cautiously optimistic about the
effects of TPE on adherence with oral anticancer treatment .
Future research should help in refining intervention methods
that may help patients who are prescribed oral anticancer
treatment to incorporate their medication behavior into self-
management behavior of their illness and its treatment.
We conclude that the material reviewed in this paper sup-
ports the view that in order to address and maximize adher-
ence with oral anticancer treatment in persons with cancer,
psychosocial determinants deserve attention first and fore-
most. Identifying illness perceptions and medication beliefs
and encouraging their adaptive functions seems to be a
worthwhile undertaking in this category of patients.
Behavioral scientists would be important in assisting health
care providers in these efforts.
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